๐Ÿ‡บ๐Ÿ‡ธ FDA

Intelligence ยท Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors โ€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text โ€” searchable for business development and competitive intelligence.

225 results for โ€œShanghaiโ€ Clear

  1. JMT108

    Shanghai University of Traditional Chinese Medicine

    Unresectable Locally Advanced or Metastatic Melanoma

    phase 2 small molecule active

    1 trial
  2. KN046 ๏ผˆPD-L1/CTLA4 BsAb๏ผ‰

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Advanced HCC

    phase 2 small molecule terminated

    1 trial
  3. LTI-01

    Shanghai Reinovax Biologics Co.,LTD

    Pleural Effusion

    phase 2 small molecule completed

    1 trial
  4. LTI-03

    Shanghai Reinovax Biologics Co.,LTD

    Idiopathic Pulmonary Fibrosis (IPF)

    phase 2 small molecule active

    1 trial
  5. LTI-03, The placebo is InhaLacยฎ 500 (micronized lactose monohyrdate).

    Shanghai Reinovax Biologics Co.,LTD

    Idiopathic Pulmonary Fibrosis

    phase 2 small molecule active

    1 trial
  6. Lynparza 100 mg film-coated tablets, CYCLOPHOSPHAMIDE, Lynparza 150 mg film-coated tablets, DOCETAXEL, DOXORUBICIN, CARBOPLATIN, EPIRUBICIN

    Shanghai Reinovax Biologics Co.,LTD

    Early invasive triple negative breast cancer with positive HRD status (acc. to Myriad mychoiceยฉ test)

    phase 2 small molecule active

    1 trial
  7. MRG003

    Shanghai University of Traditional Chinese Medicine

    Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

    phase 2 small molecule active

    1 trial
  8. ORSERDU 86 mg film-coated tablets, LETROZOLE , -, ORSERDU 345 mg film-coated tablets, Kisqali 200 mg film-coated tablets, EXEMESTANE , ANASTROZOLE

    Shanghai Reinovax Biologics Co.,LTD

    endocrine-responsive HER2-negative early breast cancer

    phase 2 small molecule active

    1 trial
  9. PD-1inhibitor

    Shanghai Chest Hospital

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial
  10. Quadrivalent influenza vaccine

    Green Valley (Shanghai) Pharmaceuticals Co.,

    Influenza

    phase 2 mab completed

    1 trial
  11. Recombinant Anti-IL-17A Humanized Monoclonal Antibody Injection

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Psoriasis

    phase 2 small molecule active

    1 trial
  12. Recombinant Anti-IL-1ฮฒ Humanized Monoclonal Antibody Injection 100 mg

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Gout Arthritis

    phase 2 small molecule active

    1 trial
  13. Recombinant Anti-interleukin-4 Receptor Alpha Monoclonal Antibody Injection (611)

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Dermatitis, Atopic

    phase 2 small molecule active

    1 trial
  14. Recombinant Human Erythropoiesis Injection (CHO cell)

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Chronic Renal Failure With Hemodialysis

    phase 2 small molecule active

    1 trial
  15. Recombinant anti-PD-1 humanized monoclonal antibody injection

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Sarcoma, Soft Tissue

    phase 2 small molecule active

    1 trial
  16. SPGL008

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    NMIBC

    phase 2 mab active

    1 trial
  17. SR419

    Shanghai University of Traditional Chinese Medicine

    Peripheral Neuropathic Pain

    phase 2 small molecule completed

    1 trial
  18. SSGJ-705

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Locally Advanced, Recurrent or Metastatic Malignancies

    phase 2 small molecule active

    2 trials
  19. SSGJ-706

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    First-line Advanced NSCLC Patients

    phase 2 small molecule active

    1 trial
  20. SSGJ-706+XELOX

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Gastric/Gastroesophageal Junction Adenocarcinoma

    phase 2 small molecule active

    1 trial
  21. SSGJ-707

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    NSCLC

    phase 2 small molecule active

    1 trial
  22. SSGJ-707

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Advanced/recurrent Endometrial Cancer and Platinum-resistant Ovarian Cancer

    phase 2 small molecule active

    1 trial
  23. SSGJ-707

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    First-line Advanced NSCLC Patients

    phase 2 small molecule active

    1 trial
  24. SSGJ-707

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1โ€“3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync โ€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources